Aquestive Therapeutics (NASDAQ:AQST) Stock Rating Reaffirmed by HC Wainwright

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report)'s stock had its "buy" rating reiterated by analysts at HC Wainwright in a report issued on Friday, Benzinga reports. They currently have a $9.00 target price on the stock. HC Wainwright's price objective would suggest a potential upside of 119.51% from the company's current price.

Other equities research analysts have also issued research reports about the stock. JMP Securities increased their price objective on shares of Aquestive Therapeutics from $8.00 to $10.00 and gave the company an "outperform" rating in a research note on Friday, March 15th. Raymond James initiated coverage on shares of Aquestive Therapeutics in a research note on Thursday, March 28th. They issued an "outperform" rating and a $7.00 price objective for the company.

Aquestive Therapeutics Price Performance

Shares of AQST stock traded down $0.06 on Friday, reaching $4.10. 2,215,438 shares of the company were exchanged, compared to its average volume of 2,166,226. The company has a market cap of $300.53 million, a price-to-earnings ratio of -29.28 and a beta of 2.87. The company has a 50-day moving average of $3.74 and a 200-day moving average of $2.53. Aquestive Therapeutics has a one year low of $1.09 and a one year high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last posted its earnings results on Tuesday, March 5th. The company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.04). The company had revenue of $13.21 million for the quarter, compared to the consensus estimate of $11.79 million. As a group, sell-side analysts predict that Aquestive Therapeutics will post -0.36 EPS for the current year.

Insider Buying and Selling at Aquestive Therapeutics

In other Aquestive Therapeutics news, insider Alexander Mark Schobel sold 50,000 shares of the stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $6.00, for a total value of $300,000.00. Following the completion of the sale, the insider now owns 984,476 shares in the company, valued at approximately $5,906,856. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 8.39% of the company's stock.

Institutional Investors Weigh In On Aquestive Therapeutics

Several large investors have recently modified their holdings of the stock. Armistice Capital LLC increased its stake in shares of Aquestive Therapeutics by 314.5% during the 3rd quarter. Armistice Capital LLC now owns 4,800,000 shares of the company's stock worth $7,344,000 after purchasing an additional 3,642,000 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Aquestive Therapeutics by 11.2% during the 4th quarter. Vanguard Group Inc. now owns 1,889,053 shares of the company's stock worth $3,816,000 after purchasing an additional 190,401 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Aquestive Therapeutics by 137.1% during the 2nd quarter. Renaissance Technologies LLC now owns 1,230,196 shares of the company's stock worth $2,030,000 after purchasing an additional 711,396 shares during the last quarter. Millennium Management LLC increased its stake in shares of Aquestive Therapeutics by 326.2% during the 2nd quarter. Millennium Management LLC now owns 1,108,764 shares of the company's stock worth $709,000 after purchasing an additional 848,584 shares during the last quarter. Finally, Essex Investment Management Co. LLC bought a new position in Aquestive Therapeutics in the 4th quarter worth approximately $1,709,000. Hedge funds and other institutional investors own 32.45% of the company's stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.